Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 11/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL724496 | 0.85 | NAMPT (0.47) | NAMPTHDAC8HDAC6KMT2A | |
| SCHEMBL10272385 | 0.83 | NAMPT (0.42) | NAMPTPARP1PARP2HDAC8HDAC6 | |
| SCHEMBL10209791 | 0.82 | KMT2A (0.50) | NAMPTHDAC8HDAC6KMT2ANPSR1 | |
| SCHEMBL719060 | 0.82 | NOTUM (0.47) | FLT3HDAC8HDAC6PDCD1CD274 | |
| SCHEMBL10224182 | 0.81 | TAAR1 (0.47) | FLT3PARP1PARP2KMT2APDCD1 | |
| SCHEMBL10224107 | 0.79 | RAB9A (0.59) | NAMPTHDAC6KMT2A | |
| SCHEMBL10224100 | 0.79 | HDAC6 (0.60) | NAMPTFLT3HDAC8HDAC6MAP3K5 | |
| SCHEMBL12922758 | 0.78 | HDAC6 (0.62) | NAMPTHDAC8HDAC6 | |
| SCHEMBL724391 | 0.77 | SMN1; SMN2 (0.61) | KMT2APDCD1CD274 | |
| SCHEMBL10224028 | 0.76 | POLB (0.57) | HDAC6MAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8471026-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-25 | — | — | US | claimed |
| US-9249142-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249142-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20150105418-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2015-04-16 | — | — | US | disclosed |
| US-20150105418-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2015-04-16 | — | — | US | disclosed |
| US-8952163-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8952163-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20140142108-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARM INC (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142108-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARM INC (US) | 2014-05-22 | — | — | US | disclosed |
| US-8471026-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8471026-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120053201-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053201-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053201-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC2 | NAMPT 3287/4885JAK2 109/4885FLT3 225/4885 |
| US-20140142108-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC2 | NAMPT 3287/4885JAK2 109/4885FLT3 225/4885 |
| US-20150105418-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC2 | NAMPT 3287/4885JAK2 109/4885FLT3 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.